These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6820039)

  • 21. A polyvalent Pseudomonas vaccine.
    Sato H; Diena BB
    Rev Can Biol; 1974 Jun; 33(2):93-7. PubMed ID: 4211759
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of pseudomonas respiratory infection in a surgical intensive care unit.
    Polk HC; Borden S; Aldrete JA
    Ann Surg; 1973 May; 177(5):607-15. PubMed ID: 4634109
    [No Abstract]   [Full Text] [Related]  

  • 23. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA; Miler JJ
    Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pseudomonas aeruginosa infection: pathogenesis and therapy.
    Pennington JE
    Compr Ther; 1979 May; 5(5):14-22. PubMed ID: 110508
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pseudomonas multicomponent vaccine in major burn patients].
    Mizuno H; Ashikawa K
    Nihon Rinsho; 1991 Oct; 49(10):2425-30. PubMed ID: 1749100
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of type specific IgG Pseudomonas antibodies by the ELISA test after administration of the anti Pseudomonas aeruginosa vaccine.
    Meitert T; Meitert E; Pencu E; Tonciu M
    Arch Roum Pathol Exp Microbiol; 1984; 43(1):53-60. PubMed ID: 6442132
    [No Abstract]   [Full Text] [Related]  

  • 27. Pseudomonas aeruginosa infection in cystic fibrosis: prevent, eradicate or both?
    Eber E; Zach MS
    Thorax; 2010 Oct; 65(10):849-51. PubMed ID: 20861286
    [No Abstract]   [Full Text] [Related]  

  • 28. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination against respiratory Pseudomonas aeruginosa infection.
    Grimwood K; Kyd JM; Owen SJ; Massa HM; Cripps AW
    Hum Vaccin Immunother; 2015; 11(1):14-20. PubMed ID: 25483510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum level of Pseudomonas aeruginosa-specific IgA in patients with chronic lower respiratory tract infection and its clinical significance].
    Tsukada H; Suzuki E; Wada K; Arakawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Oct; 31(10):1227-34. PubMed ID: 8271654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
    Grochowski J; Bilinska M; Stankiewicz D; Arkusiewicz E
    Pol Przegl Chir; 1979 Jun; 51(6):623-7. PubMed ID: 116210
    [No Abstract]   [Full Text] [Related]  

  • 32. Pseudomonas vaccination and immunotherapy: an overview.
    Holder IA
    J Burn Care Rehabil; 2001; 22(5):311-20. PubMed ID: 11570530
    [No Abstract]   [Full Text] [Related]  

  • 33. Problems and progress towards vaccination against bacterial infections of the respiratory tract.
    Artenstein MS
    Dev Biol Stand; 1975; 28():115-25. PubMed ID: 236208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of monovalent vaccines in the treatment of Pseudomonas aeruginosa infection.
    De Fajardo CL; Delfino AH; Laborde HF
    Prog Immunobiol Stand; 1971; 5():425-7. PubMed ID: 4633970
    [No Abstract]   [Full Text] [Related]  

  • 35. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
    Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
    Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
    [No Abstract]   [Full Text] [Related]  

  • 36. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiological and immunobiological implications of Pseudomonas aeruginosa epidemiological markers.
    Meitert T; Meitert E
    Arch Roum Pathol Exp Microbiol; 1981; 40(1):5-23. PubMed ID: 6821022
    [No Abstract]   [Full Text] [Related]  

  • 38. [Immunologic prevention and treatment of wound infection in open fractures and osteomyelitis].
    Bialik IF; Burdyga FA; Grigor'ev NI; Krokhina MA; Kalashnik AF
    Ortop Travmatol Protez; 1981 Aug; (8):17-21. PubMed ID: 6793953
    [No Abstract]   [Full Text] [Related]  

  • 39. [Infection and immunity in burns].
    Kolker II
    Khirurgiia (Mosk); 1980 May; (5):17-22. PubMed ID: 6772869
    [No Abstract]   [Full Text] [Related]  

  • 40. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.